A new Belgian decree has been published that sets out two pathways for importing medicines that do not have regulatory approval in the country in times of critical shortages. One pathway is for medicines that meet a special need for which treatment is unavailable in Belgium, while the other is for products that counter certain health threats.
Belgian Decree Sets Out Requirements for Importing Unlicensed Medicines.
New updates to 2006 regulations expand the existing framework governing drug shortages in Belgium.
More from Pink Sheet
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.